Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

146 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-10

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the goal of this observational study is to evaluate the role of VEXUS score and lung ultrasound to guide decongestive therapy in patients with cardiorenal syndrome type -1. the main question it aims to answer is: Can the VEXUS score and lung ultrasound guide the efffect of decongestive therapy on KFR and decongestion metrics in patients with CRS-1 compared to standard assesment ?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1

NCT05927285

Cardiorenal Syndrome Acute Kidney Injury Decompensated Heart Failure +2 more

COMPLETED NA

Accuracy of Venous Excess Ultrasound Score at Hospital Admission to Predict Acute Kidney Injury

NCT07040696

Preeclampsia Acute Kidney Injury

RECRUITING

Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

NCT02372292

Cardiorenal Syndrome

COMPLETED NA

External Validation of the VExUS Score for the Prediction of Acute Renal Failure in Cardiac Surgery

NCT05640518

Renal Failure Acute Renal Failure Renal Insufficiency +1 more

UNKNOWN

VExUS Score and AKI in Critically Ill Adult patients-a Prospective Observational Study.

NCT06889116

Acute Kidney Injury VExUS

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiorenal Syndrome Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

the VEXUS group :in this group we use the vexus score to guide decongestive theapy

the use of diuretic if vexus score more than 1 at time of enrollement

Group Type ACTIVE_COMPARATOR

frusemide

Intervention Type DRUG

in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group

the lung US group : we use lung ultrasound score to detect degree of pulmonary congestion

if lung ultrasound score more than 15 we will start diuretic therapy

Group Type ACTIVE_COMPARATOR

frusemide

Intervention Type DRUG

in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

frusemide

in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients of both genders aged 18-65 years old.

* Patients with CRS1 criteria (worsening of renal function due to acute heart failure manifested by : ( Dyspnea , orthopnea ,hypoxia , congested neck veins , oliguria and congestion in imaging.)
* Patients with Modified lung ultrasound score(LUSS) more than 15.

Exclusion Criteria

* • Refusal to participate.

* Patients with renal transplantation.
* Unknowing baseline creatinine.
* Patients with a life-threatening indication of RRT (defined as intractable hyperkalemia, acidosis, uremic symptoms) at enrollment,
* RRT before recruitment,
* known prehospitalization advanced chronic kidney disease (defined by an estimated GFR \<30 mL/min/1.73 m2 or chronic RRT),
* use of extracorporeal membrane oxygenation (ECMO),
* diagnosis of hepatic cirrhosis or other condition with portal hypertension
* Or postrenal causes of AKI

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes